Table 5.
Item | Groups | --P-- | ||||
---|---|---|---|---|---|---|
Control | Sildenafil | Mucuna pruriens | Tribulus terrestris | Ashwagandha | ||
AST, U/L | 97.50 ± 8.92 | 118.86 ± 33.73 | 99.29 ± 15.85 | 104.29 ± 21.86 | 108.51 ± 23.25 | >0.05 |
ALT, U/L | 46.67 ± 6.50 | 59.86 ± 10.48 | 48.71 ± 6.78 | 47.71 ± 10.24 | 50.00 ± 10.05 | >0.05 |
ALP, U/L | 204.00 ± 43.32a | 202.14 ± 31.02a | 161.86 ± 29.29b | 215.86 ± 25.58a | 202.00 ± 22.03a | 0.0349 |
CK, U/L | 531.00 ± 224.85 | 399.29 ± 292.28 | 405.86 ± 189.07 | 226.86 ± 102.12 | 331.40 ± 44.57 | >0.05 |
Urea, mg/dl | 33.00 ± 2.61 | 36.43 ± 2.07 | 36.14 ± 5.08 | 36.00 ± .3.74 | 36.80 ± 6.18 | >0.05 |
Creatine, mg/dl | 0.30 ± 0.03 | 0.28 ± 0.03 | 0.28 ± 0.04 | 0.29 ± 0.02 | 0.30 ± 0.03 | >0.05 |
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, CK creatine kinase control, no treatment; Sildenafil, rats treated with Sildenafil (5 mg/kg/d); Mucuna, rats treated with Mucuna pruriens (300 mg/kg bw); Tribulus; rats treated with Tribulus terrestris (300 mg/kg bw); Ashwagandha; rats treated with Ashwagandha (300 mg/kg bw). Data are LS means ± SE (n = 7). Different superscripts in the same row (a–c) indicate group mean differences (p < 0.05)